Personalized mRNA vaccine succeeds in phase 3 melanoma trial after ~50% phase 2 benefit
A personalized mRNA vaccine plus Keytruda improved recurrence-free and distant metastasis-free survival in a phase 3 trial of more than 1,100 patients with melanoma. The earlier phase 2 trial showed roughly a 50% reduction in recurrence or death at 5 years. Approval might come as early as 2027, and trials are under way in other cancers.